Last reviewed · How we verify
Remifentanil + Lidocaïne
Remifentanil + Lidocaïne is a Opioid analgesic + Local anesthetic combination Small molecule drug developed by University Hospital, Montpellier. It is currently in Phase 3 development for Perioperative analgesia and sedation during surgical procedures, Local anesthetic adjunct in anesthesia protocols. Also known as: Ultiva® + Xylocaïne®.
Remifentanil is a potent opioid agonist that provides analgesia and sedation, while lidocaine is a local anesthetic that blocks sodium channels to provide local pain relief.
Remifentanil is a potent opioid agonist that provides analgesia and sedation, while lidocaine is a local anesthetic that blocks sodium channels to provide local pain relief. Used for Perioperative analgesia and sedation during surgical procedures, Local anesthetic adjunct in anesthesia protocols.
At a glance
| Generic name | Remifentanil + Lidocaïne |
|---|---|
| Also known as | Ultiva® + Xylocaïne® |
| Sponsor | University Hospital, Montpellier |
| Drug class | Opioid analgesic + Local anesthetic combination |
| Target | Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Analgesia |
| Phase | Phase 3 |
Mechanism of action
Remifentanil acts as a mu-opioid receptor agonist in the central nervous system, producing rapid-onset analgesia and sedation suitable for perioperative use. Lidocaine blocks voltage-gated sodium channels in nerve fibers, preventing action potential propagation and providing local anesthetic effects. The combination is used to provide both systemic analgesia and local anesthetic benefit during procedures.
Approved indications
- Perioperative analgesia and sedation during surgical procedures
- Local anesthetic adjunct in anesthesia protocols
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
- Nausea and vomiting
- Local injection site reactions
Key clinical trials
- Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide (PHASE3)
- Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass (NA)
- Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil + Lidocaïne CI brief — competitive landscape report
- Remifentanil + Lidocaïne updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI
Frequently asked questions about Remifentanil + Lidocaïne
What is Remifentanil + Lidocaïne?
How does Remifentanil + Lidocaïne work?
What is Remifentanil + Lidocaïne used for?
Who makes Remifentanil + Lidocaïne?
Is Remifentanil + Lidocaïne also known as anything else?
What drug class is Remifentanil + Lidocaïne in?
What development phase is Remifentanil + Lidocaïne in?
What are the side effects of Remifentanil + Lidocaïne?
What does Remifentanil + Lidocaïne target?
Related
- Drug class: All Opioid analgesic + Local anesthetic combination drugs
- Target: All drugs targeting Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
- Manufacturer: University Hospital, Montpellier — full pipeline
- Therapeutic area: All drugs in Anesthesia/Analgesia
- Indication: Drugs for Perioperative analgesia and sedation during surgical procedures
- Indication: Drugs for Local anesthetic adjunct in anesthesia protocols
- Also known as: Ultiva® + Xylocaïne®
- Compare: Remifentanil + Lidocaïne vs similar drugs
- Pricing: Remifentanil + Lidocaïne cost, discount & access